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Immunity in Medicine 
M. Saeed 
Department of Biological and Biomedical Sciences, The Aga Khan University, Karachi. 
Cancer therapy breakthroughs 
Lung cancer is the leading cause of cancer related 
deaths worldwide. Recently tyrosine kinase inhibitor 
therapy with imatinib (Gleevec) has already revolutionized 
the treatment of chronic myelogenous leukemia and other 
tumours with activating mutation in these kinases. Inhibitor 
of Epidermal Growth Factor Receptor (EGFR) tyrosine 
kinase, Gefitinib (Iressa) was approved in Japan and USA 
for treatment of non-small cell lung carcinoma (NSCLC), 
the rationale being the overexpression of EGFR in lung 
carcinoma tissue compared to adjacent normal tissue. 
Clinical trials however, revealed high variability in drug 
response. Two Boston groups1,2 independently screened 
EGFR gene for mutations in NSCLC tumors. They 
discovered mutations in exons 18 through 21 which were 
either, small, in-frame deletions or amino acid substitutions 
clustered around the tyrosine kinase domain of EGFR. The 
surrounding normal tissue did not possess the mutations, 
proving that they were somatic in origin. Additionally, these 
mutations were only present in gefitinib responsive patients, 
being most frequent in adenocarcinomas. In vitro culture 
studies showed that the cell line harboring mutations in the 
EGFR gene was 50 times more sensitive to genfitinib than 
other cell lines. 
The identification of EGFR mutations in a subset of 
NSCLC and the association between these mutations and 
gefitinib sensitivity demonstrate that alteration in protein 
structure and not only the expression levels, render tumors 
sensitive to particular drugs. 
Cetuximab is a monoclonal antibody against the 
EGFR. It h.:s been shown that combination therapy of 
advanced colorectal cancer with cetuximab and irinotecan 
causes disease regression in approximately 22 percent of 
patients. Vascular endothelial growth factor (VEGF) is an 
important regulator of angiogenesis. Bevacizumab is a 
monoclonal antibody against VEGF. A small clinical trial 
involving patients who had received no previous therapy for 
advanced colorectal cancer showed that the addition of 
bevacizumab to flourauracil and leucovorin increased the 
response rate from 17 percent to 40 percent. This phase 3 
trial3 
 was initiated when the addition of irinotecan to 
fluorouracil and leucovorin (IFL) had just been shown to 
prolong survival in patients with metastatic colorectal 
cancer and was considered the new standard first-line 
therapy for this disease. The results showed that the addition 
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of bevacizumab to IFL was associated with increases in the 
median overall survival (20.3 months vs. 15.6 months); 
median duration of progression-free survival (10.6 months 
vs. 6.2 months); response rate (44.8 percent vs. 34.8 
percent); and the median duration of response (10.4 months 
vs. 7.1 months). Hypertension was noted as the only side-
effect of bevacizumab combination therapy. The results of 
this phase 3 study3 provide support for the use of 
antiangiogenic agents in the treatment of cancer. 
1. Paez JG et al. EGFR mutations in lung cancer: correlation with clinical 
response to gefitinib therapy. Science. 2004 Jun; 304(5676):1497-500. 
2. Lynch TJ et al. Activating mutations in the epidermal growth factor receptor 
underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl 
J Med. 2004 May 20;350(20:2129-39. 
3. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for 
metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. 
Vaccine against Hepatitis C 
A potential vaccine against HCV is presented in a 
thesis from Karolinska Institute, Sweden. HCV is a major 
cause of chronic liver disease affecting 170 million people 
worldwide. Antiviral therapy with interferon alpha and 
ribavarin is used quite effectively but about 60% patients 
become chronic HCV carriers. HCV infection has a high 
rate of viral persistence, thought to be mediated through its 
high genetic variability. This severely compromises vaccine 
development. Two regions of HCV are genetically stable —
the core and the NS3 protein, a non-structural protein with 
protease and helicase properties. Previous attempts at 
vaccine development against these proteins have resulted in 
poor immunological responses. Frelin and colleagues' 
noted that when NS4A, a cofactor of NS3 was included in 
the protein complex used for immunization of mice, there 
was a more rapid and increased antibody response. The T-
cell (predominantly TH1) mediated response was similarly 
boosted. Finally the authors evaluated the transdermal 
delivery of this immunogen using the gene gun approach 
which has already been validated in humans and 
demonstrated that the NS3/4A complex was able to 
immunize adequately. 
1. Frelin L et al. Low dose and gene gun immunization with a hepatitis C virus 
nonstructural (NS)3 DNA-based vaccine containing NS4A inhibit NS3/4A-
expressing tumors in vivo. Gene Then 2003 Apr;10(8):686-99. 
2. Lam Frelin, lars.frelin@labmed.ki.se 
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Parasite coat uncovers links in Asthma 
Asthma is thought to result from an exaggerated TH2 
airway inflammation. Striking similarities exist between the 
TH2 responses in asthma and in antiparasitic immune 
reactions. Thus it is believed that TH2 inflammation evolved 
to deal with parasites and that allergy and atopic asthma 
arise when these immunological responses are poorly 
controlled, independent of parasitic infection. Chitin is the 
second most abundant polysaccharide in nature and is found 
in fungal cell walls and in exoskeletons of crustaceans and 
sheaths of nematodes. Degrading enzymes called chitinases 
keep chitin concentration in check. Recently acid 
mammalian chitinase (AMCase) group of enzymes of 
unknown function have been described in humans. Zhu et 
al.] investigated the role of AMCase in TH2 mediated 
inflammation in mice and showed that AMCase expression 
was increased in lung epithelial cells and macrophages after 
challenge with an aeroallergen. Subsequent experiments 
demonstrated that this response was stimulated by TH2 cells 
and did not occur in the absence of IL-13. Marked decrease 
in inflammation occurred when mice were treated with 
chitinase inhibitor, allosamidin. These findings add to our 
understanding of the pathogenesis of asthma in a number of 
ways — first, the genetic expression ability of chitinases 
could be an important determinant in an individual's 
susceptibility to asthma and atopy; second AMCase has an 
optimium pH of 2.3 which resolves with steroid therapy and 
thus the beneficial effects of steroids in asthma may be in 
part mediated through decreasing bioactivity of AMCase; 
thirdly, AMCase is a potential therapeutic target for asthma 
and related disorders. 
Zhu et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-
13 pathway activation. Science. 2004 Jun 11;304(5677):1678-82, 
Tuberculosis and Typhoid survival strategies 
Pathogenicity of mycobacteria and salmonella is 
tightly linked to intracellular survival, but some species of 
these organisms have evolved strategies to survive 
intracellularly and avoid degradation. Walburger et al.' 
found that a kinase, called protein kinase G (PknG) is 
secreted by pathogenic mycobacteria into macrophage 
phagosomes which inhibited phagosome-lysosome fusion 
preventing degradation of invading microbes. They also 
discovered an inhibitor of PknG which has the potential of 
being used as an anti-tuberculous drug. Hernandez et aI2, 
discovered that a phosphatase, called SopB, is secreted into 
the host cells by Salmonella and plays a crucial role in the 
formation of spacious phagosomes. These large vesicles 
provide a favourable environment where Salmonella can 
reside and establish its replicative niche. Deletion of the 
gene for SopB resulted in the virtual absence of large 
phagosomes and a significantly decreased Salmonella 
survival. 
1. Walburger A et al. Protein kinase G from pathogenic mycobacteria promotes 
survival within macrophages. Science. 2004 Jun 18;304(5678):1800-4, 
2. Hernandez LD et al. Salmonella modulates vesicular traffic by altering 
phosphoinositide metabolism. Science. 2004 Jun 18;304(5678):1805-7, 
Errata 
In JPMA Volume 54, No. 6, June 2004 issue, page 330, under Case Report, viz: "Anesthetic Management of Combined 
Caesarean Section and Clipping of Ruptured Cerebral Aneurysm", name of the second author has erroneously been printed 
as S. F. Hoda. It should be corrected to read as S. F. Hasan. 
In the classified advertisement published in Volume 54, No. 7, July 2004 issue, page No. 356 and in Volume 54 No. 8, 
August 2004 issue, page No. 407, the name of the city is erroneously printed as Toronto, Ontaria, Canada. It should be 
corrected to read as Toronto, Ontario, Canada. 
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